In a patient who recently completed treatment for bacterial vaginosis and vulvovaginal candidiasis and now has persistent thick white (occasionally green) vaginal discharge with vulvar erythema, what are the typical clinical presentation and findings of cytolytic vaginosis?

Cytolytic Vaginosis: Clinical Presentation

Cytolytic vaginosis presents with thick white vaginal discharge, vulvar itching, dyspareunia, and dysuria in the setting of low vaginal pH (≤4.5), with microscopy showing abundant lactobacilli, fragmented epithelial cells (cytolysis), naked nuclei, and false clue cells—critically without evidence of Candida, Trichomonas, or bacterial vaginosis. 1, 2

Key Clinical Features

Symptoms

• Vaginal discharge: Thick, white discharge (occasionally described as green in some cases) 1, 3
• Vulvar pruritus: Often cyclical, worsening during the luteal phase of the menstrual cycle 4
• Dyspareunia: Present in the majority of cases 2, 3
• Dysuria: Vulvar dysuria (external burning with urination) 4, 3
• Cyclical pattern: Symptoms characteristically increase during the luteal phase 4

Physical Examination Findings

• Vulvar erythema: Present in symptomatic patients 2
• Vulvar edema: May be observed
• Vaginal discharge: White, thick discharge without the characteristic odor of bacterial vaginosis

Diagnostic Criteria

The diagnosis requires all of the following 1, 2, 5:

Laboratory Findings

• Vaginal pH ≤ 4.5 (typically 3.5-4.5) - sensitivity 100%, specificity 86% 1, 4
• Microscopy (Gram stain or wet mount):
  • Abundant/excessive lactobacilli (sensitivity 100%, specificity 56%) 1
  • Epithelial cytolysis with fragmented cells (sensitivity 80%, specificity 99%) 1
  • Naked nuclei from lysed epithelial cells 2, 5
  • False clue cells (epithelial cells covered with lactobacilli, not bacteria) - sensitivity 70%, specificity 99% 1
  • Absent or minimal leukocytes 1, 2, 5

Exclusion Criteria (Must be Absent)

• No Candida species (spores, hyphae, or pseudohyphae) 1, 2, 5
• No Trichomonas vaginalis 1, 2
• No bacterial vaginosis (no clue cells, normal pH for BV would be >4.5) 1

Clinical Context for Your Patient

In a patient who recently completed treatment for both bacterial vaginosis and vulvovaginal candidiasis but continues to have persistent thick white discharge with vulvar erythema, cytolytic vaginosis should be strongly considered. This scenario is classic for CV, as:

1. The condition is frequently misdiagnosed as recurrent VVC 2, 5, 6, leading to repeated unnecessary antifungal treatments
2. CV has a high recurrence rate of 61.5% 3, explaining persistent symptoms
3. The prevalence of CV among women with vaginitis symptoms ranges from 19.4% to 32.1% 1, 3, making it far more common than traditionally recognized

Key Distinguishing Features from VVC

The critical microscopic differences that separate CV from VVC 5:

Feature	Cytolytic Vaginosis	Vulvovaginal Candidiasis
Lactobacilli	Overgrowth/abundant	Variable (present or absent)
Epithelial cells	Fragmented, cytolysis, naked nuclei	Normal, intact
Candida	Absent	Present (spores, hyphae)
Leukocytes	Minimal to absent	Variable
pH	≤4.5	4.0-4.5

Common Pitfalls

• Misdiagnosis as recurrent VVC: This is the most common error, leading to unnecessary antifungal therapy that will not resolve symptoms 2, 5, 6
• Relying on symptoms alone: The symptoms of CV overlap significantly with VVC, making microscopy essential 5, 3
• Telephone prescriptions: Patients often self-diagnose as "yeast infection" and request treatment without examination, perpetuating misdiagnosis 4
• Not considering CV in the differential: Many clinicians are unaware of this condition, as it remains under-recognized despite its prevalence 6, 3

Microbiological Insight

Lactobacillus crispatus dominates the vaginal flora in women with CV 6, and the excessive lactobacilli produce lactic acid that lowers vaginal pH to levels that cause epithelial cell lysis—the hallmark of this condition.

Treatment Approach

Once diagnosed, CV responds to sodium bicarbonate (baking soda) sitz baths to raise vaginal pH and reduce lactobacilli overgrowth 2, 4, 3. This treatment showed symptom resolution in 81% of patients with complete cessation of discharge and 96-97% resolution of dyspareunia 2. The treatment efficacy was 58.8% in another recent study 3, indicating moderate but meaningful benefit.

The key takeaway: In your patient with persistent symptoms after treating BV and VVC, obtain microscopy specifically looking for cytolysis, abundant lactobacilli, and naked nuclei while confirming the absence of Candida—this will prevent further unnecessary antifungal treatments and allow appropriate therapy with alkalinizing agents.